1. Home
  2. PRPO vs GDTC Comparison

PRPO vs GDTC Comparison

Compare PRPO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • GDTC
  • Stock Information
  • Founded
  • PRPO N/A
  • GDTC 2018
  • Country
  • PRPO United States
  • GDTC Singapore
  • Employees
  • PRPO N/A
  • GDTC N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • GDTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRPO Industrials
  • GDTC Health Care
  • Exchange
  • PRPO Nasdaq
  • GDTC Nasdaq
  • Market Cap
  • PRPO 22.0M
  • GDTC 21.5M
  • IPO Year
  • PRPO N/A
  • GDTC 2023
  • Fundamental
  • Price
  • PRPO $17.59
  • GDTC $1.88
  • Analyst Decision
  • PRPO
  • GDTC Buy
  • Analyst Count
  • PRPO 0
  • GDTC 1
  • Target Price
  • PRPO N/A
  • GDTC $5.00
  • AVG Volume (30 Days)
  • PRPO 16.8K
  • GDTC 14.8K
  • Earning Date
  • PRPO 11-05-2025
  • GDTC 01-01-0001
  • Dividend Yield
  • PRPO N/A
  • GDTC N/A
  • EPS Growth
  • PRPO N/A
  • GDTC N/A
  • EPS
  • PRPO N/A
  • GDTC N/A
  • Revenue
  • PRPO $21,242,000.00
  • GDTC $368,838.00
  • Revenue This Year
  • PRPO N/A
  • GDTC $5.37
  • Revenue Next Year
  • PRPO N/A
  • GDTC N/A
  • P/E Ratio
  • PRPO N/A
  • GDTC N/A
  • Revenue Growth
  • PRPO 27.05
  • GDTC N/A
  • 52 Week Low
  • PRPO $3.90
  • GDTC $1.20
  • 52 Week High
  • PRPO $22.38
  • GDTC $4.05
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 54.11
  • GDTC 46.04
  • Support Level
  • PRPO $17.00
  • GDTC $1.82
  • Resistance Level
  • PRPO $22.38
  • GDTC $2.28
  • Average True Range (ATR)
  • PRPO 1.35
  • GDTC 0.12
  • MACD
  • PRPO -0.13
  • GDTC 0.00
  • Stochastic Oscillator
  • PRPO 40.83
  • GDTC 13.04

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: